Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP trimmed its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 0.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,029,369 shares of the company’s stock after selling 4,558 shares during the quarter. Wellington Management Group LLP owned 2.75% of Entrada Therapeutics worth $16,449,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of TRDA. Los Angeles Capital Management LLC bought a new stake in shares of Entrada Therapeutics in the 3rd quarter worth approximately $542,000. Connor Clark & Lunn Investment Management Ltd. grew its position in Entrada Therapeutics by 132.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company’s stock worth $2,215,000 after buying an additional 78,953 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new position in shares of Entrada Therapeutics in the third quarter valued at $1,109,000. Renaissance Technologies LLC acquired a new stake in shares of Entrada Therapeutics during the 2nd quarter valued at $636,000. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Entrada Therapeutics by 3.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock worth $814,000 after acquiring an additional 2,146 shares in the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Entrada Therapeutics Trading Down 2.5 %

Shares of TRDA stock opened at $17.66 on Friday. The company has a market capitalization of $660.84 million, a price-to-earnings ratio of 11.11 and a beta of -0.18. Entrada Therapeutics, Inc. has a 1-year low of $11.35 and a 1-year high of $21.79. The stock’s fifty day simple moving average is $18.41 and its 200-day simple moving average is $16.62.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on TRDA shares. Roth Capital raised Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. HC Wainwright boosted their price objective on Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Roth Mkm initiated coverage on shares of Entrada Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $29.00 target price for the company. Finally, Oppenheimer lifted their target price on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 6th.

Insider Buying and Selling at Entrada Therapeutics

In other news, CFO Kory James Wentworth sold 8,637 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $19.98, for a total transaction of $172,567.26. Following the completion of the sale, the chief financial officer now directly owns 73,849 shares of the company’s stock, valued at $1,475,503.02. This trade represents a 10.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of Entrada Therapeutics stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $20.77, for a total value of $476,359.95. Following the sale, the insider now owns 4,402,849 shares of the company’s stock, valued at approximately $91,447,173.73. This represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,128 shares of company stock valued at $875,551 in the last 90 days. 7.59% of the stock is currently owned by corporate insiders.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.